Serum β-endorphin level in patients with depression on fluvoxamine

Farmaco

Volumn 54, Issue 3, 1999, Pages 130-133

  Djurović, Dragan ^a   Milić Aškrabić, Jelena ^b   Majkić Singh, Nada ^c  

^a Institute for Occupational Health of Serbia   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Depression; Drug monitoring; Immunometric analysis; Serotonergic systems; Serum levels; endorphin

Indexed keywords

BETA ENDORPHIN; FLUVOXAMINE MALEATE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG MONITORING; ENDOGENOUS DEPRESSION; FEMALE; HAMILTON SCALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; SEROTONINERGIC SYSTEM;

EID: 0344603651     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(99)00005-1     Document Type: Article

References (22)

1. Vanree J.M. Neuropeptides and psychopathology. J. Cont. Rel. 29:1994;307-315.
2. Meltzer H.Y., Lowy M.T. The serotonin hypothesis of depression. Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. 1987;513 Raven Press, New York.
3. Maes M., Meltzer H.Y. The serotonin hypothesis of major depression. Meltzer H.Y. Psychopharmacology: The Fourth Generation of Progress. 1995;933 Raven Press, New York.
4. Musselman D.L., Nemeroff C.B. Adrenal function in major depression. Endocrinologist. 5:1995;91-96.
5. Ferris R.M., Brieaddy L., Mehta N., Jollingsworth E., Rigdon G., Wang C., Soroko F., Wastila W., Cooper B. Pharmacological properties of 403U76, a new chemical class of 5-hydroxytryptamine and noradrenaline reuptake inhibitors. J. Pharm. Pharmacol. 47:1995;775-781.
6. Garcia Sevilla J.A., Ahtee L., Magnussm T., Carrlsson A. Opiate receptor mediated changes in monoamine synthesis in rat brain. J. Pharm. Pharmacol. 30:1978;613-621.
7. Barchas J., Madden J., Weber E., Evans C.J., Berger P.A. Endorphins and Depression: Potential for New Approaches, Drugs in Psychiatry. 1:1983;325 Elsevier, Amsterdam.
8. Claassen V., Davies J.E., Hertting G., Placheta P. Fluvoxamine: a specific 5-hydroxytryptamine uptake inhibitor. Br. J. Pharmacol. 60:1977;505-516.
9. Benfield P., Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 32:1986;313-334.
10. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. 1994;American Psychiatric Association, Washington, DC.
11. Zimmerman P., Coryell W., Pfohl B., Stangl D. Four definitions of endogenous depression and the dexamethasone suppression test. J. Affect. Disord. 8:1985;37-45.
12. Bech P., Gram L.F., Reisby N., Rafaelsen O.J. The WHO depression scale: relationship to the Newcastle Scale. Acta Psychiatr. Scand. 62:1980;140-153.
13. Guelfi J.D., Dreyfus J.F., Ruschel S., Blanchard C., Pichot P. Structure factorielle de L'échelle de depression de Hamilton. J. Ann. Médico. Psychol. 139:1981;199-213.
14. W. Guy, ECDU Assessment Manual for Psychopharmacology, DHEW Publication, 76 (1976) 338.
15. Galard R., Gallart J., Arguello J.M., Schwartz S., Castellanos J.M., Catalan R. Plasma levels of β-endorphin, cortisol, prolactin and growth hormone in depressed patients. Acta Psychiatr. Scand. 78:1988;230-233.
16. Matthews J., Ahil H., Greden J., Charney D., Weinberg V., Rosenbaum A., Watson S.J. β-Endorphin/β-lipotropin immunoreactivity in endogenous depression. Arch. Gen. Psychiatry. 43:1986;374-381.
17. Sapun D.I., Farah J.M., Mueller G.P. Evidence that a serotonergic mechanism stimulates the secretion of pituitary β-endorphin-like immunoreactivity in the rat. Endocrinology. 109:1981;421-426.
18. Dave J.R., Eiden L.E., Karanian J.W., Eskay R.L. Ethanol exposure decreases pituitary corticotrophin-releasing factor binding, adenylate cyclase activity, proopiomelanocortin biosynthesis, and plasma β-endorphin levels in the rat. Endocrinology. 118:1988;280-286.
19. Rupprecht R., Lesch K.P., Muller U., Beck G., Bechmann H., Schulte H.M. Blunted adrenocorticotropin, but normal β-endorphin release after human corticotrophin-releasing hormone administration in depression. J. Clin. Endocrinol. Metab. 69:1989;600-603.
20. Gianoulakis C., Chan J.D., Kalant H., Chretien M. Chronic ethanol treatment alters the biosynthesis of β-endorphin by the rat neurointermediate lobe. Can. J. Physiol. Pharmacol. 61:1983;967-976.
21. Petraglia F., Penalva A., Genazzani A.R., Müller E.E. Stimulation of β-endorphin and β-lipotropin release from the anterior but not the neurointermediate pituitary lobe in the rat after acute administration of serotonin-acting drugs. Life Sci. 31:1982;2809-2817.
22. Blier P., de Montigny G., Chaput Y.A. Role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J. Clin. Psychiatry. 51:1990;14-20.